When you lose weight through a calorie-restricted diet, your HDL-cholesterol levels can shift in complex ways — and your ABCG1 genotype at rs692383 appears to determine how much HDL-c you preserve during that process. ABCG1¹¹ ABCG1
ATP-binding cassette transporter G1, a membrane pump that moves cholesterol and phospholipids from macrophage cell membranes onto mature HDL particles — the second step in reverse cholesterol transport after ABCA1 initiates HDL loading is one of the body's primary cholesterol efflux transporters. Located on chromosome 21q22.3 and expressed in macrophages, liver, and many other tissues, ABCG1 loads surplus cellular cholesterol onto mature HDL particles, funneling it back to the liver — a central step in preventing foam cell accumulation and atherosclerotic plaque formation.

The rs692383 variant is an intronic variant in ABCG1 at chromosome 21, position 42,215,064 (GRCh38). It does not alter the ABCG1 protein sequence but sits within a region where intronic variants can influence gene expression, splicing efficiency, or regulatory element responsiveness to metabolic signals. What distinguishes rs692383 is its documented interaction with calorie-restricted dietary conditions: the G allele at this position is associated with better preservation of HDL-c levels during weight-loss dieting.

The Mechanism

The precise molecular mechanism by which rs692383 modifies ABCG1's response to calorie restriction is not yet established. However, ABCG1 transcription is regulated by liver X receptor (LXR)²² liver X receptor (LXR)
a nuclear receptor activated by oxysterols and dietary lipid signals; once activated, LXR drives expression of ABCG1, ABCA1, and other cholesterol homeostasis genes. During calorie restriction, circulating lipid profiles shift substantially: fatty acid mobilization increases, HDL remodeling accelerates, and ABCG1 activity modulates how efficiently cholesterol is transferred to and from HDL particles.

An intronic variant in this regulatory context could influence how strongly the ABCG1 gene responds to these dietary metabolic signals — for instance, by altering an enhancer element or splice site that controls expression levels under conditions of negative energy balance. AA homozygotes may have a less robust ABCG1 response during calorie restriction, resulting in less efficient cholesterol recycling through HDL and a net decline in circulating HDL-c. G allele carriers appear to maintain ABCG1 efflux activity more effectively under these conditions, preserving HDL-c levels even while losing weight.

The Evidence

The primary evidence comes from a study by Teixeira et al. (2020)³³ study by Teixeira et al. (2020)
Teixeira MD et al. Is it possible ABC transporters genetic variants influence the outcomes of a weight-loss diet in obese women? Genetics and Molecular Biology, 2020 examining 137 obese women following a nine-week calorie-restricted diet (−600 kcal/day). G allele carriers showed a significantly lower reduction in HDL-c compared to AA homozygotes (p=0.043), and this association remained significant after correction for multiple testing in the longitudinal analysis. A secondary finding — association between the AA genotype and lower BMI in the post-diet period — did not survive multiple-testing correction.

The evidence base for rs692383 is currently at the emerging level: a single study with a modest sample size (137 women), focused on one specific context (obese women undergoing calorie restriction), with no independent replication to date. The biological plausibility is solid — ABCG1 is a well-characterized HDL efflux transporter — but the specific effect of rs692383 on HDL-c during dieting requires confirmation in larger and more diverse populations.

The global G allele frequency is approximately 0.46, with substantial population stratification: ~31% in Europeans, ~76% in Africans, and ~46% in East Asians. This variation means the population-level relevance of this finding differs markedly by ancestry.

Practical Actions

For AA homozygotes (~29% of people globally, ~47% of Europeans): calorie-restricted dieting may reduce HDL-c more than expected. This does not mean weight loss should be avoided — the metabolic benefits of appropriate weight management outweigh a modest HDL-c dip in most cases. However, tracking HDL-c before, during, and after a weight-loss intervention gives personalized data on whether this genotype-specific response is occurring. If HDL-c falls substantially during dieting, specific interventions can offset this effect: regular aerobic activity is one of the most potent HDL-raising strategies, EPA/DHA supplementation modestly supports HDL remodeling, and niacin (extended-release) raises HDL-c specifically — though it should only be considered under medical supervision.

For G allele carriers (AG or GG): HDL-c appears more resilient during calorie restriction, which may provide a cardiovascular advantage during weight-loss periods. Standard dietary monitoring is appropriate.

Interactions

ABCG1 at rs692383 is one of three independent ABCG1 variants in this database. The rs4148102 variant modifies LDL-c response to high-PUFA diets, and the rs57137919 promoter variant alters ABCG1 expression in macrophages and is associated with altered HDL-c and LDL-c levels at baseline. Together, these three variants define distinct aspects of ABCG1 biology: promoter regulation, dietary PUFA response, and HDL-c dynamics during calorie restriction. Carrying risk alleles at multiple ABCG1 variants may compound impairment in reverse cholesterol transport, though no study has directly examined the rs692383 × rs4148102 or rs692383 × rs57137919 interaction.

Adiponectin is one of the body's most potent insulin-sensitizing hormones, secreted by adipose tissue and acting on the liver and muscle to reduce fat accumulation and improve glucose handling. Its actions depend entirely on two receptors: AdipoR1 and AdipoR2¹¹ AdipoR2
AdipoR2: adiponectin receptor 2, encoded by ADIPOR2 on chromosome 12p13.33. Primarily activates PPARα signaling in liver and adipose tissue, enhancing fatty acid oxidation and suppressing glucose production. rs767870 sits in intron 6 of ADIPOR2, and the G allele at this locus has been linked to impaired receptor signaling, elevated liver fat content, and increased type 2 diabetes (T2D) risk in replicated studies across European populations.

The Mechanism

ADIPOR2 encodes a seven-transmembrane receptor with intrinsic ceramidase activity that converts ceramide — a pro-apoptotic and insulin-antagonizing lipid — into the cytoprotective sphingosine 1-phosphate. When adiponectin binds AdipoR2, the receptor activates PPARα²² PPARα
PPARα: peroxisome proliferator-activated receptor alpha, a nuclear transcription factor that drives expression of fatty acid oxidation genes, particularly in liver cells, which then transcribes genes for β-oxidation, reducing ectopic fat and hepatic triglyceride output. Independently, AdipoR2 activation engages AMPK³³ AMPK
AMPK: AMP-activated protein kinase, the cell's central energy sensor; activation inhibits glucose production (gluconeogenesis) and stimulates glucose uptake to suppress hepatic glucose production.

rs767870 is located in intron 6, 20 nucleotides downstream of the codon 650 splice junction (HGVS: NM_001375363.1:c.650+20G>A). As an intronic variant, it does not alter the encoded protein, but intronic variants commonly affect splicing efficiency, mRNA stability, or the binding of intronic regulatory elements — all of which can reduce receptor abundance at the cell surface. Less functional ADIPOR2 means weaker PPARα induction per unit of circulating adiponectin, attenuating the receptor-mediated reduction of liver fat and hepatic insulin resistance.

The Evidence

The primary genetic evidence comes from a Caucasian case-control study⁴⁴ Caucasian case-control study
Vaxillaire M et al. Genetic analysis of ADIPOR1 and ADIPOR2 candidate polymorphisms for type 2 diabetes in the Caucasian population. Diabetes, 2006 of 2,876 French subjects. Among three ADIPOR2 SNPs showing nominal T2D association, rs767870 was the one replicated in an independent dataset, reaching OR 1.25 (95% CI 1.07–1.45, p=0.0051) in the pooled meta-analysis. The G allele — the minor allele at ~15% frequency in Europeans — is the risk allele.

The metabolic consequences extend beyond T2D susceptibility. A Finnish multi-cohort study⁵⁵ A Finnish multi-cohort study
Kotronen A et al. Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. European Journal of Endocrinology, 2009 found rs767870 significantly associated with liver fat content measured by proton magnetic resonance spectroscopy (¹H-MRS) in Finnish subjects, with the association validated in two further cohorts via gamma-glutamyltransferase and fasting triglyceride levels — both accepted surrogate markers of hepatic fat. This places rs767870 in the liver-fat category alongside rs738409 (PNPLA3) and rs58542926 (TM6SF2), though with more moderate effect.

A Greek cross-sectional study⁶⁶ A Greek cross-sectional study
Halvatsiotis I et al. Genetic variation in ADIPOR2 is associated with coronary artery disease and increased ADIPOR2 expression in peripheral monocytes. Cardiovascular Diabetology, 2010 found significantly different rs767870 genotype distributions between CAD and non-CAD individuals (p=0.017), with heterozygous carriers showing worse endothelial function (lower flow-mediated dilatation) and higher intima-media thickness — early markers of atherosclerotic burden.

The evidence is rated moderate: the T2D association was replicated within the same French study across independent cohorts, and consistent pleiotropic effects on liver fat and vascular phenotypes suggest genuine biological activity at this locus. However, rs767870 has not appeared in the largest T2D GWAS meta-analyses (DIAGRAM, UKBB), likely reflecting its moderate effect size (OR ~1.25) and ~15% MAF, which give it limited power in studies not specifically focused on ADIPOR2.

Practical Actions

For AG and GG carriers, the main levers are those that directly amplify adiponectin signaling or compensate for impaired PPARα induction: omega-3 fatty acids (EPA/DHA) are independent PPARα ligands that partially bypass the receptor step; aerobic exercise robustly raises plasma adiponectin and upregulates ADIPOR2 expression in muscle; and reduced saturated fat intake lowers the ceramide substrate that impaired AdipoR2 ceramidase activity handles less efficiently.

Liver fat monitoring is particularly actionable: serum ALT and gamma-GT provide inexpensive early signals of hepatic fat accumulation that can guide dietary intervention before overt hepatic steatosis develops.

Interactions

ADIPOR2 acts in the same adiponectin signaling axis as ADIPOR1 (rs1044498), which primarily signals through AMPK rather than PPARα. Carriers of risk alleles at both receptors face a doubly attenuated adiponectin response — reduced AMPK activation (AdipoR1) and reduced PPARα induction (AdipoR2) — potentially producing greater combined insulin resistance than either variant alone. A compound action for the combined genotype is warranted if rs1044498 risk alleles are also present.

PPARG rs1801282 (Pro12Ala) is a functional variant in the PPARγ gene that affects adipogenesis and adiponectin secretion upstream of ADIPOR2 signaling. Carriers of the Ala12 (G) allele at rs1801282 tend to have higher circulating adiponectin but greater adipose tissue (more substrate for the receptor). The combined effect of elevated adiponectin (PPARG Ala12) and impaired receptor (ADIPOR2 G allele) has not been characterized in a single published study but represents a plausible pathway interaction for compound action design.

The SPINK5 gene encodes LEKTI¹¹ LEKTI
Lympho-Epithelial Kazal-Type Inhibitor, a 15-domain serine protease inhibitor expressed in skin, thymus, and mucosal surfaces; it acts as the primary brake on kallikrein proteases that drive epidermal desquamation, the protease inhibitor central to skin barrier integrity. Genetic variants across SPINK5 have been associated with atopic dermatitis since the landmark Walley et al. study²² Walley et al. study
Gene polymorphism in Netherton and common atopic disease. Nat Genet, 2001 identified the gene's role in common allergic disease. rs2303065 sits in exon 13 of SPINK5 and changes the codon for histidine at position 396 from CAT to CAC — a synonymous substitution that does not alter the LEKTI protein sequence (His396=).

The Mechanism

The c.1188T>C change at rs2303065 does not alter any amino acid in LEKTI and has no known direct functional consequence on protease inhibitor activity. ClinVar classifies this variant as benign based on submissions from multiple independent clinical testing laboratories with no conflicts. The T allele's clinical relevance arises entirely from its physical proximity to the functional rs2303067 variant³³ rs2303067 variant
SPINK5 p.Lys420Glu, 843 bp downstream in the same exon 13 region; Lys420 increases furin-mediated cleavage of the LEKTI D6–D7 linker, impairing the potent D6–D9 inhibitory fragment and elevating KLK5/KLK7 kallikrein activity in the skin. These two variants are in tight linkage disequilibrium within the exon 13 risk haplotype: the T allele of rs2303065 and the A (Lys420) allele of rs2303067 are inherited together more often than chance would predict.

The consequence of impaired LEKTI function — the mechanism tagged by this haplotype — is well characterised: KLK5 and KLK7 kallikreins run with reduced inhibition, cleaving desmoglein-1 and accelerating corneodesmosomes breakdown, increasing transepidermal water loss. Simultaneously, elevated kallikrein activity upregulates TSLP⁴⁴ TSLP
thymic stromal lymphopoietin, a cytokine that polarises dendritic cells toward Th2 immune responses and initiates the atopic sensitisation cascade in keratinocytes, lowering the threshold for IgE-mediated sensitisation to environmental allergens.

The Evidence

The rs2303065 T allele was among seven of eight SPINK5 polymorphisms found to be significantly associated with atopic dermatitis in a Japanese cohort of 124 AD patients and 110 healthy controls by Kato et al.⁵⁵ Kato et al.
Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br J Dermatol, 2003. This finding was extended by Nishio et al.⁶⁶ Nishio et al.
Association between polymorphisms in the SPINK5 gene and atopic dermatitis in the Japanese. Genes Immun, 2003 using transmission disequilibrium tests, which confirmed SPINK5 haplotype-level association with AD but not asthma, and noted cross-ethnic consistency.

A large European analysis by Weidinger et al.⁷⁷ Weidinger et al.
Analysis of SPINK5, KLK7, and FLG polymorphisms and eczema risk. J Allergy Clin Immunol, 2008 (2,774 AD cases, 10,607 controls) found that SPINK5 variants showed only modest association at the population level, primarily through maternal transmission — a finding consistent with an LD proxy effect that varies in strength across populations with different haplotype structures. Because rs2303065 tags rather than causes the LEKTI impairment, the magnitude of its association with AD depends on how tightly it co-segregates with the functional rs2303067 variant in a given population — an LD parameter that differs between Japanese, European, and African cohorts.

The overall evidence is best classified as moderate: replicated across independent Japanese cohorts using different statistical methods, with a plausible mechanistic explanation via LD, but attenuated in large European studies and with no independent functional pathway.

Practical Actions

Because rs2303065 has no protein-altering effect, its actionability derives entirely from the underlying LEKTI pathway impairment it tags. Carrying the T allele — particularly in homozygous form — signals an increased likelihood of also carrying the risk haplotype at rs2303067. The practical implications are the same as for impaired LEKTI activity: supporting the skin barrier proactively, identifying allergen sensitisers that exploit a more permeable barrier, and monitoring for early atopic features in childhood.

Interactions

LD relationship with rs2303067: This is the primary interaction. Carriers of the TT genotype at rs2303065 are enriched for the Lys420/Lys420 (AA) genotype at rs2303067, the directly functional variant. For users who have results for both SNPs, the rs2303067 result provides the mechanistic information; rs2303065 provides LD-based corroboration.

SPINK5 × FLG variants: SPINK5 haplotype risk and filaggrin (FLG) loss-of-function variants operate through parallel mechanisms — protease over-activity vs. structural scaffold loss — and their effects on AD risk appear additive rather than synergistic, as documented in the Weidinger 2008 analysis.

The SNCA gene¹¹ SNCA gene
Alpha-synuclein (SNCA) was the first gene linked to Parkinson's disease; it encodes the protein that forms the pathological hallmark of PD — Lewy bodies contains multiple independent risk variants. rs356219 sits approximately 9 kilobases downstream of SNCA in a regulatory region that controls how much alpha-synuclein protein the cell produces. Unlike rs356182 — which acts through neuronal differentiation pathways — rs356219 works primarily by upregulating SNCA gene expression: carriers of the G allele have measurably higher alpha-synuclein levels in blood and specific brain regions. This is the variant's defining characteristic, and it makes rs356219 one of the most actionable SNCA risk markers because elevated alpha-synuclein is directly tied to aggregation, Lewy body formation, and dopaminergic neuron death.

The G allele has been consistently identified as a risk factor across twelve or more independent case-control studies spanning European, East Asian, and South American populations, making it one of the most robustly replicated common SNCA risk variants²² one of the most robustly replicated common SNCA risk variants.

The Mechanism

rs356219 functions as a regulatory variant³³ regulatory variant
A variant that alters gene expression rather than protein sequence; these often reside in promoters, enhancers, or 3′UTR regions in the 3′ region of the SNCA locus. The G allele alters the activity of this regulatory element in a direction that boosts SNCA transcription. Studies in CD45+ blood cells⁴⁴ Studies in CD45+ blood cells
Circulating immune cells express SNCA and can serve as a peripheral proxy for central nervous system expression confirmed that individuals carrying the G allele have significantly elevated SNCA mRNA levels and higher alpha-synuclein protein concentrations compared to AA homozygotes. Similarly, plasma alpha-synuclein is elevated in G-allele carriers in a dose-dependent additive manner⁵⁵ plasma alpha-synuclein is elevated in G-allele carriers in a dose-dependent additive manner, suggesting each additional G allele incrementally raises the ambient level of this aggregation-prone protein.

The downstream consequence is straightforward: more alpha-synuclein means a higher probability of misfolding, oligomer formation, and ultimately aggregation into the insoluble fibrils that kill dopaminergic neurons in the substantia nigra. This dose-response model explains why GG homozygotes show earlier onset and more rapid cognitive decline than AG heterozygotes, who in turn show higher risk than AA individuals.

The Evidence

The seminal genetic association study⁶⁶ The seminal genetic association study
Mata et al. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Archives of Neurology, 2010 enrolled 1,956 PD patients and 2,112 controls and identified rs356219 as the most significant SNCA marker (OR 1.41, 95% CI 1.28–1.55; p=1.6×10⁻¹²). Crucially, the study also measured plasma alpha-synuclein in a subset, demonstrating that the risk allele correlates with higher protein levels — establishing a plausible dose-response mechanism.

A Chinese Han population study⁷⁷ A Chinese Han population study
Pan et al. SNP rs356219 of the alpha-synuclein gene is associated with Parkinson's disease in a Chinese Han population. Parkinsonism & Related Disorders, 2012 (403 patients, 315 controls) found OR 1.88 (95% CI 1.27–2.78) for variant genotypes, with GG homozygotes comprising 42.2% of PD patients versus 32.4% of controls. A follow-up Chinese study of 685 patients ⁸⁸ Li et al. SNCA rs356219 variant increases risk of sporadic Parkinson's disease in ethnic Chinese. Am J Med Genet B, 2013 confirmed these findings with OR 1.81 (95% CI 1.54–2.13; p=5.71×10⁻¹³) and documented earlier age at disease onset in G-allele carriers.

A 2025 systematic review and meta-analysis⁹⁹ A 2025 systematic review and meta-analysis
Common SNCA genetic variants and Parkinson's disease risk. International Journal of Molecular Sciences, 2025 across 27 studies found rs356219 demonstrated the strongest risk association of any common SNCA variant, particularly under the recessive model (OR 1.69, 95% CI 1.49–1.92). Under the allelic model the overall OR was 1.35 (95% CI 1.22–1.50).

A 2021 systematic review¹⁰¹⁰ A 2021 systematic review
Pedersen et al. A systematic review of associations between common SNCA variants and clinical heterogeneity in PD. npj Parkinson's Disease, 2021 covering 58 studies confirmed that the most reproducible clinical association for any common SNCA variant is rs356219 and earlier age at onset of PD. A Brazilian cohort study ¹¹¹¹ Campelo et al. Variants in SNCA gene are associated with PD risk and cognitive symptoms. Front Aging Neurosci, 2017 found that GG homozygotes with PD showed OR 5.74 (95% CI 1.42–23.21) for cognitive impairment, and a Scandinavian longitudinal study confirmed that GG genotype associates with faster annual cognitive decline as measured by MMSE.

A gene-environment study¹²¹² A gene-environment study
Lucchini et al. Metal exposure and SNCA rs356219 polymorphism associated with Parkinson disease. Front Neurol, 2020 of 432 cases and 444 controls in an industrially exposed Italian region found that the homozygous risk genotype alone confers OR 2.03 for PD, and that metal exposure independently adds further risk — with a directional (though not statistically significant) interaction suggesting carriers face compounded hazard when exposed to manganese and other neurotoxic metals.

Practical Actions

The central mechanism — elevated alpha-synuclein due to higher SNCA expression — shapes the specific interventions that make sense for G-allele carriers. The goal is not to lower risk of developing any disease, but to slow the aggregation of the excess protein that this variant produces.

Coenzyme Q10 targets several mechanisms directly relevant to alpha-synuclein toxicity¹³¹³ Coenzyme Q10 targets several mechanisms directly relevant to alpha-synuclein toxicity: mitochondrial complex I dysfunction (the primary energy failure in PD), oxidative stress that promotes alpha-synuclein misfolding, and neuroinflammation. The ubiquinol form is preferred for absorption. Coffee and caffeine have shown consistent neuroprotective associations in PD¹⁴¹⁴ Coffee and caffeine have shown consistent neuroprotective associations in PD, including evidence that caffeine reduces the toxicity of alpha-synuclein oligomers and restores autophagy — the cellular process that clears misfolded protein aggregates.

Reducing exposure to neurotoxic metals is particularly relevant for this variant: manganese specifically promotes alpha-synuclein overexpression and aggregation, and the gene-environment interaction data for rs356219 support avoiding occupational or environmental manganese/heavy metal exposure. Pesticides containing manganese compounds (maneb, mancozeb) are a specific concern for agricultural workers.

For those who develop PD, knowing the rs356219 genotype may inform prognosis: GG homozygotes face higher risk of cognitive decline and should discuss early cognitive monitoring with their neurologist.

Interactions

rs356219 is distinct from and independent of rs356182 (another SNCA risk variant already profiled in this database). These two variants reside in different linkage disequilibrium blocks and likely confer risk through different mechanisms — rs356182 acting through neuronal differentiation, rs356219 through SNCA expression levels. Carriers of risk alleles at both loci may face incrementally higher cumulative PD susceptibility.

The most clinically significant interaction is with LRRK2 G2019S, the most common dominant PD mutation. In LRRK2 G2019S carriers, the rs356219 G allele shifts age of onset approximately 4 years earlier¹⁵¹⁵ In LRRK2 G2019S carriers, the rs356219 G allele shifts age of onset approximately 4 years earlier (AG+GG carriers: mean onset ~58 years vs AA carriers: ~62 years; p=0.006). Individuals who carry both LRRK2 G2019S and rs356219 G risk alleles represent a high-priority group for early monitoring and preventive intervention.

rs356165, another 3′-region SNCA variant, co-occurs with rs356219 in some studies and may contribute additional independent risk, though its LD relationship with rs356219 varies by ancestry.

The SLC19A1 gene encodes the reduced folate carrier (RFC1), the primary mechanism by which folate moves from the bloodstream into your cells. Without efficient RFC1 function, intracellular folate levels fall — even when blood folate appears normal. The rs3788200 variant sits in intron 2 of SLC19A1 and has no direct effect on protein structure, but it serves as a reliable molecular tag for the same haplotype as rs1051266, the well-studied G80A coding variant that directly reduces folate transport kinetics.

The Mechanism

rs3788200 is an intronic variant that does not itself change amino acid sequence. Its biological relevance comes from its position in the genome: it is in very strong linkage disequilibrium¹¹ very strong linkage disequilibrium
LD r²=0.98 — the two variants co-occur nearly perfectly across populations with rs1051266 (G80A, p.His27Arg), which directly alters transmembrane domain 1 of the RFC1 transporter protein and reduces folate uptake into cells. Carrying the G allele at rs3788200 therefore marks the same genetic background as carrying the T allele at rs1051266: reduced folate transport capacity.

The Evidence

A 2023 Italian cohort study Bugianesi et al. Biomedicines, 2023²² Bugianesi et al. Biomedicines, 2023
Impaired Function of Solute Carrier Family 19 Leads to Low Folate Levels and Lipid Droplet Accumulation in Hepatocytes genotyped 756 individuals (452 NAFLD cases, 304 controls) and found rs3788200 significantly associated with non-alcoholic fatty liver disease (p=0.003). The G allele was associated with higher NAFLD risk, while the A allele was protective (0.6-fold decreased MAFLD risk). The LD with rs1051266 (r²=0.98) confirmed these two variants represent the same functional haplotype — impaired SLC19A1 transport reduces intracellular folate, dysregulates hepatic lipid metabolism genes, and promotes lipid droplet accumulation.

A family-based transmission disequilibrium test O'Byrne MR et al. Birth Defects Research, 2010³³ O'Byrne MR et al. Birth Defects Research, 2010
Association of SLC19A1 genes with meningomyelocele in 610 families found rs3788200 significantly associated with meningomyelocele risk (p=0.0195). Only 37 of 97 informative transmissions passed the G allele to affected offspring — fewer than expected — suggesting the G allele on its own shows a complex pattern, with the intronic variant's effect mediated through its LD relationship with the coding variant rs1051266.

A 2022 Chinese pharmacogenomics study Cen H et al. Pharmacogenomics and Personalized Medicine, 2022⁴⁴ Cen H et al. Pharmacogenomics and Personalized Medicine, 2022 of 104 rheumatoid arthritis patients on methotrexate found rs3788200 G-carrier status (AG+GG) associated with significantly better EULAR treatment response (RR=1.45, 95% CI=1.04–2.01, p=0.03). This seeming paradox — the G allele associated with reduced folate transport yet better methotrexate response — is mechanistically coherent: methotrexate enters cells via the same RFC1 transporter, so the G-tagged rs1051266-T haplotype may affect drug accumulation dynamics differently than folate in the context of pharmacological dosing.

Practical Implications

The clinical significance of rs3788200 runs parallel to rs1051266. If you carry the G allele, your folate transport efficiency is likely reduced, making adequate dietary and supplemental folate more important. Methylfolate (5-MTHF) is the preferred form — it is already in its active state and may be transported more efficiently than synthetic folic acid. Monitoring homocysteine provides a functional readout: elevated homocysteine signals that methylation is falling behind, potentially due to limited intracellular folate availability.

If you are prescribed methotrexate (for rheumatoid arthritis, psoriasis, or other conditions), your SLC19A1 genotype at this locus may influence how the drug accumulates in your cells. Inform your prescribing physician of this variant; dosing and monitoring protocols may benefit from adjustment.

Interactions

rs3788200 is in strong LD (r²=0.98) with rs1051266 and the two should be interpreted together — they report on the same underlying folate-transport haplotype. The combined effect is amplified when MTHFR variants (rs1801133, rs1801131) are also present: impaired methylfolate production (MTHFR) combined with reduced folate import (SLC19A1) creates a more significant bottleneck in the folate-methylation cycle than either variant alone. rs1888530, another SLC19A1 intronic variant (intron 5), showed even stronger meningomyelocele association in the O'Byrne 2010 study and may tag a partially distinct haplotype within the same gene.

CYP2C19 is one of the most important drug-metabolizing enzymes in the liver, responsible for processing a wide range of medications including anticoagulants, proton pump inhibitors, antidepressants, and antifungals. While much attention focuses on the well-characterized loss-of-function variants (*2, *3) and the gain-of-function *17 allele, rs3814637 is a separate upstream regulatory variant located approximately 1,400 bases before the CYP2C19 transcription start site. Carriers of the T allele show altered CYP2C19-mediated drug metabolism, with the most robust evidence coming from warfarin dosing studies.

The Mechanism

Rs3814637 sits in the regulatory region upstream of CYP2C19¹¹ Located ~1,374–1,393 bp upstream of the CYP2C19 transcription start site per Ensembl VEP and is classified as an upstream gene variant. The precise molecular mechanism by which the T allele alters CYP2C19 activity has not been fully characterized in published literature, but the pharmacokinetic data consistently show that T-allele carriers have higher plasma concentrations of CYP2C19 substrates, suggesting either reduced enzyme activity or expression. Unlike the *2 allele's splice-site mutation, rs3814637 likely exerts its effect through altered transcription factor binding or promoter-region regulation.

Warfarin exists as two enantiomers²² Mirror-image forms of the same molecule with different metabolic fates: S-warfarin (more potent, metabolized mainly by CYP2C9) and R-warfarin (metabolized predominantly by CYP1A2, CYP3A4, and CYP2C19). The rs3814637 variant specifically affects R-warfarin clearance, meaning T-allele carriers clear this enantiomer more slowly, raising the effective anticoagulant exposure.

The Evidence

The strongest evidence for rs3814637 comes from a 2022 meta-analysis by Wang et al.³³ 2022 meta-analysis by Wang et al.
Wang D et al. Impact of CYP2C19 gene polymorphisms on warfarin dose requirement: a systematic review and meta-analysis. Pharmacogenomics, 2022 analyzing nine studies totaling 1,393 patients. Individuals with the TT genotype required 34% lower warfarin maintenance doses than CC carriers; CT heterozygotes required 18% less. A companion pharmacokinetic study by Lane et al. (2012)⁴⁴ Lane et al. (2012)
Lane S et al. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol, 2012 independently identified rs3814637 as one of the key genetic determinants of R-warfarin clearance in a long-term anticoagulation cohort.

For other CYP2C19 substrates, a Chinese lung-cancer study by Tan et al. (2022)⁵⁵ Tan et al. (2022)
Tan T et al. Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer. Front Pharmacol, 2022 found that TT+CT carriers showed significantly higher peak plasma concentrations of anlotinib — a multikinase inhibitor — and elevated rates of hypertension and hemoptysis compared to CC carriers. This is consistent with a broader pattern of reduced CYP2C19-mediated clearance in T-allele carriers.

Practical Actions

The most direct clinical implication is for warfarin dosing. Anyone prescribed warfarin who carries the T allele — particularly TT homozygotes — may need a lower starting dose and closer INR monitoring during initiation. The effect is modest for heterozygotes (CT, ~18% dose reduction) but more pronounced for homozygotes (TT, ~34% reduction). Standard warfarin dosing algorithms do not currently include rs3814637, so this information is supplementary to — not a replacement for — clinical INR monitoring and algorithmic dosing (e.g., IWPC or WarfarinDosing.org algorithms that already incorporate CYP2C9 and VKORC1).

The T allele is enriched in East Asian populations (15–17% in Japanese cohorts) compared to Europeans (~6%), which may partly explain observed population differences in warfarin sensitivity.

Interactions

Rs3814637 acts independently of the major CYP2C19 star alleles (*2 via rs4244285 and *17 via rs12248560). A person carrying both rs3814637 T and the *2 no-function allele (rs4244285 A) would have compounded reductions in CYP2C19-mediated warfarin metabolism. Conversely, carrying rs3814637 T alongside *17 (rs12248560 T) creates opposing effects in the CYP2C19 locus and could complicate pharmacokinetic prediction. The *2 and *17 alleles are already captured by separate GeneOps entries; this entry reflects the independent additive contribution of rs3814637.

Glucose-6-phosphate dehydrogenase (G6PD) is a housekeeping enzyme present in every cell, but it is most critically important in red blood cells — which have no mitochondria and therefore depend entirely on G6PD as their sole source of NADPH¹¹ NADPH
Nicotinamide adenine dinucleotide phosphate (reduced form) — a cellular reducing agent essential for regenerating glutathione and neutralizing oxidative stress. When G6PD activity is severely reduced, oxidative stress from certain drugs, foods, or infections overwhelms the red cell's antioxidant defenses, causing the cell membrane to rupture — a process called acute hemolytic anemia²² acute hemolytic anemia
Sudden, triggered destruction of red blood cells causing jaundice, dark urine, fatigue, and anemia that can require blood transfusion.

The rs5030868 A allele creates the G6PD Mediterranean variant — a missense change (c.563C>T on the coding strand) that substitutes serine with phenylalanine at position 188 of the mature protein (p.Ser188Phe, MANE Select transcript). This substitution disrupts a dimer interface contact residue, severely destabilizing the active enzyme structure and reducing G6PD activity to less than 10% of normal — classified by the WHO as Class II severe deficiency³³ Class II severe deficiency
Class II variants retain 1–10% of normal enzyme activity and cause acute hemolytic crises under oxidative challenge; Class I (most severe) causes chronic hemolysis even at rest. G6PD deficiency is the most common human enzymopathy, affecting more than 400 million people worldwide⁴⁴ affecting more than 400 million people worldwide
Cappellini & Fiorelli, Lancet 2008; geographic distribution mirrors historic malaria endemicity, and the Mediterranean variant is the predominant severe form across the Mediterranean basin, Middle East, and South Asia, where allele frequencies reach 1–10% in some sub-populations.

The Mechanism

G6PD catalyzes the first and rate-limiting step of the pentose phosphate pathway: converting glucose-6-phosphate to 6-phosphogluconate while reducing NADP⁺ to NADPH. In red blood cells, this NADPH is the only means of regenerating reduced glutathione, the cell's primary intracellular antioxidant. When NADPH falls below a critical threshold — triggered by oxidative challenge from drugs, fava bean ingestion (which liberates vicine and convicine, potent pyrimidine glycoside oxidants), or febrile infection — unprotected hemoglobin is oxidized, forms Heinz bodies⁵⁵ Heinz bodies
Precipitates of denatured hemoglobin that attach to the red cell membrane and trigger rapid removal by the spleen, and the red cell is destroyed.

The Ser188Phe substitution places a bulky aromatic phenylalanine residue at a dimer interface contact point, severely disrupting the quaternary structure on which G6PD catalytic activity depends. Mason et al. 2007⁶⁶ Mason et al. 2007
Blood Reviews; review of 160 G6PD mutations; severe variants predominantly destabilize dimer interface or structural NADP-binding residues identify this class of structural disruptions as responsible for the near-complete loss of enzyme activity in Class II variants. At <10% residual activity, the Mediterranean variant provides insufficient NADPH buffering capacity even under moderate oxidative challenge — lower than the Class III variants common in Africa (~10–60% residual), and substantially more dangerous in terms of hemolytic threshold.

Because the G6PD gene is on the X chromosome, the variant is X-linked: males carrying the A allele are hemizygous and express the full severe deficiency phenotype. Females with one A copy are carriers and may have partial-to-full deficiency depending on X-chromosome inactivation⁷⁷ X-chromosome inactivation
Random silencing of one X chromosome per cell; if the wild-type allele is preferentially silenced (skewed inactivation), a heterozygous female can have enzyme activity as low as a hemizygous male.

The Evidence

ClinVar VCV000100057⁸⁸ VCV000100057 classifies this variant as Pathogenic/Likely pathogenic based on 63 submissions (48 pathogenic with multiple submitters, no conflicts) — the highest evidence tier. Conditions include nonspherocytic hemolytic anemia due to G6PD deficiency, favism (fava-bean triggered hemolysis), malaria susceptibility, and neonatal hyperbilirubinemia.

A critical and underappreciated clinical consequence of G6PD deficiency is its interference with HbA1c measurements. Because G6PD-deficient red cells have shorter lifespans, hemoglobin accumulates less glycation, producing systematically lower HbA1c readings despite normal or elevated blood glucose. Breeyear et al. 2024 (Nature Medicine)⁹⁹ Breeyear et al. 2024 (Nature Medicine)
Adaptive selection at G6PD and disparities in diabetes complications; 42 institutions across the US found that G6PD deficiency masked pre-diabetic hyperglycemia in the years before clinical diabetes diagnosis, and estimated that 12% of diabetic retinopathy cases and 9% of neuropathy cases in African ancestry participants of the ACCORD trial were attributable to underdiagnosed/undertreated hyperglycemia caused by suppressed HbA1c readings. A case report by Danzig et al. 2011¹⁰¹⁰ A case report by Danzig et al. 2011
Adolescent with G6PD deficiency and type 1 diabetes; HbA1c consistently discordant with blood glucose measurements; hemolysis reduced red cell lifespan and glycated hemoglobin accumulation further illustrates this diagnostic pitfall in an individual patient.

Regarding drug safety, Youngster et al. 2010¹¹¹¹ Youngster et al. 2010
Drug Safety systematic review of MEDLINE, PubMed, Cochrane; evidence-based review of hemolysis-inducing drugs in G6PD-deficient patients identified seven drugs with solid evidence for prohibition: primaquine, dapsone, rasburicase, nitrofurantoin, methylene blue, phenazopyridine, and toluidine blue. The risk is particularly severe for Class II variants like G6PD Mediterranean because the minimal residual enzyme activity provides almost no buffer against oxidative drug stress.

Practical Actions

The primary goal for carriers of the G6PD Mediterranean variant is identifying and avoiding oxidative triggers before an acute crisis occurs. Seven drugs have solid evidence for hemolysis induction in G6PD-deficient patients and must be flagged with prescribing physicians before any new prescription. Fava beans (broad beans, Vicia faba) and their pollen must also be completely avoided. When an acute hemolytic episode occurs — sudden pallor, jaundice, dark or tea-colored urine — immediate medical evaluation is required; severe Class II crises can require blood transfusion.

For diabetes screening, carriers should request fasting plasma glucose (FPG) or a 2-hour oral glucose tolerance test (OGTT) as the primary screening method rather than relying on HbA1c alone, which will read artificially low. If HbA1c is the only test available, treat any value above 5.5% with heightened concern and correlate with self-monitored blood glucose values.

Interactions

rs5030868 (G6PD Mediterranean) can co-occur with rs2230037 (G6PD c.376A>G, p.Asn126Asp) on the same chromosome, forming a compound allele with further reduced enzyme activity. Individuals carrying rs5030868 should ideally have rs2230037 assessed to determine whether the compound allele is present, as this would shift management toward even greater vigilance and neonatal jaundice screening planning.

The HbA1c interference from G6PD deficiency interacts critically with diabetes screening protocols relying exclusively on HbA1c. Concurrent hemoglobinopathies (e.g., sickle cell trait, thalassemia) — which co-segregate with G6PD Mediterranean in overlapping populations — further complicate HbA1c reliability and compound the diagnostic challenge.

Your hormones don't act directly on cells — they bind to receptors that activate relay proteins called heterotrimeric G proteins. The G-protein beta-3 subunit (GNB3) is one of these essential relay molecules, present in virtually every cell in your body. The C825T polymorphism (rs5443) at exon 10 of the GNB3 gene¹¹ The C825T polymorphism (rs5443) at exon 10 of the GNB3 gene
A synonymous C-to-T change that does not alter the amino acid sequence but dramatically changes how the mRNA is processed triggers alternative splicing that removes 41 amino acids from the protein — creating a shortened, more constitutively active variant called Gβ3-s. The result is a signaling amplifier: every hormone, neurotransmitter, and growth factor that acts through a G-protein-coupled receptor (GPCR) gets a louder response in T-allele carriers.

This makes GNB3 C825T one of the most pleiotropic common variants ever described. The same molecular change raises blood pressure, shifts body weight set-points, alters how well antidepressants work, and even modulates sleep timing — because all of these systems rely on GPCR signaling through the very subunit this variant modifies.

The Mechanism

In a normal heterotrimeric G protein, the alpha, beta, and gamma subunits dissociate upon receptor activation to trigger downstream cascades. The T allele of rs5443 causes deletion of nucleotides 498–620 of exon 9 during mRNA splicing²² The T allele of rs5443 causes deletion of nucleotides 498–620 of exon 9 during mRNA splicing
The variant lies in exon 10 but acts as a splicing enhancer element that disrupts exon 9 recognition, producing the Gβ3-s protein lacking 41 amino acids and one WD-repeat domain.

The mechanistic picture is more nuanced than the original "gain-of-function" framing suggested. Biochemical studies show Gβ3-s cannot form stable complexes with Gγ or Gα subunits³³ Biochemical studies show Gβ3-s cannot form stable complexes with Gγ or Gα subunits
Smrcka and Sternweis established that Gβγ dimerization requires the WD-repeat domain that Gβ3-s has lost, and the protein cannot localize to the plasma membrane normally. A more recent model proposes the mechanism runs through GRK2 regulation: wild-type Gβ3 assembles an E3 ubiquitin ligase (DDB1-CUL4A-ROC1) that targets GRK2 for ubiquitination and degradation. The Gβ3-s splice variant disrupts this Gβ3-DDB1 binding⁴⁴ The Gβ3-s splice variant disrupts this Gβ3-DDB1 binding
Without ubiquitination, GRK2 accumulates and blunts receptor desensitization, sustaining signaling. The net cellular result — enhanced, prolonged GPCR signal throughput — is well-replicated even if the precise molecular mechanism remains under investigation.

In vascular smooth muscle cells this leads to heightened Na⁺/H⁺ exchanger activity, sodium retention, and cell proliferation⁵⁵ heightened Na⁺/H⁺ exchanger activity, sodium retention, and cell proliferation
Known mechanisms linking G-protein over-activation to hypertension. In adipocytes, augmented Gi signaling reduces cAMP-mediated lipolysis, shifting fat storage balance. In serotonin and norepinephrine receptor pathways, sustained signaling alters mood regulation — which is where antidepressant pharmacogenetics comes in.

The Evidence

The original discovery by [Siffert et al. (1998) | Nature Genetics 1998; PMID 9545495] found the T allele at a frequency of 53% in hypertensives versus 44% in normotensives, and showed that lymphocytes carrying the T allele had 2–4-fold enhanced responses to Gi-coupled stimulation. Subsequent research has extended across multiple phenotypes.

Blood pressure and cardiovascular risk: [A meta-analysis of 34 studies including 14,094 hypertensive cases and 17,760 controls | Siffert group meta-analysis, J Hypertens 2007; PMID 17278960] found carriers of two T alleles (TT genotype) had OR 1.08 (95% CI 1.01–1.15) for hypertension, and TT+CT carriers combined had OR 1.17 (95% CI 1.06–1.29) versus CC. In a [cohort of 932 middle-aged Austrians | Zweier et al. Arterioscler Thromb Vasc Biol 2003; PMID 12624279], T allele carriers showed 60% higher odds of advanced carotid plaques (OR 1.61, 95% CI 1.00–2.58) and significantly lower insulin sensitivity in abdominally obese men (~9% reduction, P=0.012).

Antidepressant response: [A 2014 meta-analysis | Li et al. Prog Neuropsychopharmacol Biol Psychiatry; PMID 25451402] found the T allele (both allele and dominant models) was significantly associated with better antidepressant response in major depressive disorder, with the association strongest in Asian populations and absent in Caucasians. An independent study of [166 unipolar depression patients | Arias et al. 2007; PMID 17460549] showed the GNB3 T allele was significantly associated with antidepressant response after 2nd-line treatment (remission OR 0.18, P=0.02 for lack of remission with T allele — meaning T allele carriers were much more likely to achieve remission).

Sleep and circadian timing: [A sleep study | Parsons et al. J Sleep Res 2014; PMID 24635757] found a significant association between GNB3 rs5443 and global Pittsburgh Sleep Quality Index scores (recessive model, P=0.005), and combined analysis across cohorts linked the T allele to a mild preference for morningness. G-protein signaling in the suprachiasmatic nucleus modulates circadian pacemaking, providing a plausible mechanistic link.

Obesity and metabolic syndrome: Results are population-dependent. Meta-analyses suggest TT homozygotes have modestly elevated obesity risk in some populations, and T allele carriers responding better to non-pharmacological weight loss programs — while the CC genotype benefits more from pharmacological intervention (sibutramine, now withdrawn). Taiwanese and some East Asian cohorts show null or reversed associations for BMI, indicating strong gene-environment interaction: the T allele's metabolic effects appear most pronounced in obesogenic environments.

Practical Implications

For those with the CT or TT genotype and elevated blood pressure, standard dietary sodium restriction (targeting under 2,000 mg/day) may be especially effective given the enhanced Na⁺/H⁺ exchange activity linked to this variant. Potassium-rich foods (legumes, leafy greens, avocado) can offset sodium's vasopressor effects. If blood pressure remains uncontrolled, this variant may inform pharmacogenetic selection — beta-blockers and certain G-protein-modulating antihypertensives have shown differential efficacy by genotype.

For those with depression and the T allele, the antidepressant evidence (while mixed by ethnicity) suggests there is no pharmacogenetic reason to avoid standard first-line treatment; if anything, T-allele carriers may respond relatively well to antidepressants in some populations. Discuss your complete pharmacogenomic profile with a prescriber before making treatment decisions.

For CC homozygotes: a counterintuitive finding is that the wild-type CC genotype may carry higher metabolic risk in non-obese contexts (elevated triglycerides and cholesterol in normal- weight Taiwanese subjects) and responds less well to behavioral weight-loss interventions alone.

Interactions

GNB3 rs5443 has been examined in interaction with serotonin pathway genes in depression. [A study of antidepressant response | PMID 19560507] found a significant gene-gene interaction between GNB3 (rs5443) and HTR2A (rs6311, the serotonin 2A receptor promoter variant), as well as a 3-locus model involving GNB3 × HTR2A × SLC6A4. Since G-protein beta subunits serve downstream of serotonin receptors (5-HT1A, 5-HT2A, and others are GPCRs), functional differences in both the receptor and the G-protein effector could combine to alter signaling magnitude in an epistatic fashion.

A [Korean diurnal preference study | PMID 27660894] found a synergistic interaction among the GNB3 C/T SNP (rs5443), the ARNTL C/T SNP, and a PER2 G/A SNP on the risk of eveningness preference — suggesting GNB3-mediated signaling interacts with core clock components to shape circadian phenotype.

Compound implication for GNB3 rs5443 (CT or TT) + HTR2A rs6311 (CC or CT): Carriers of both the GNB3 T allele and the HTR2A T102C variant may have a combined effect on serotonergic G-protein signal transduction that influences antidepressant response beyond what either variant predicts alone. If considering antidepressant pharmacogenomics, both variants are worth discussing with a clinician familiar with psychiatric pharmacogenetics.

Hepatic lipase (HL), encoded by the LIPC gene on chromosome 15, is the enzyme that finishes the job of remodeling lipoprotein particles at the liver surface. After lipoprotein lipase strips triglycerides from VLDL particles in peripheral tissues, the remnants — and the large HDL2 particles that have absorbed cholesterol from arterial walls — arrive at the liver. HL then hydrolyzes their remaining triglycerides and phospholipids, converting HDL2 into the smaller, denser HDL3 particles that are primed for another round of reverse cholesterol transport.

rs8034802 is an intronic variant in LIPC. Unlike the well-characterized promoter variants rs1532085, rs1800588 (-514C>T), and rs2070895 (-250G>A) — which sit in transcription factor binding sites and directly reduce LIPC expression — rs8034802's functional mechanism is not yet fully characterized. What is documented is its association with the same downstream phenotype: higher baseline HDL-C in A allele carriers, alongside a meaningful interaction with lifestyle modification.

The Mechanism

The A allele at rs8034802 is in the same directional pathway as the known LIPC eQTL variants: carriers show elevated total HDL-C, which reflects slowed remodeling of HDL2 into HDL3 rather than increased production of transport-active HDL. When HL activity is reduced, large HDL2 particles accumulate in circulation. This raises the number reported on a standard HDL-C test while the functional capacity of those particles — their efficiency at extracting cholesterol from arterial walls and delivering it to the liver — may not increase proportionally.

The triglyceride side is the other half of the picture. HL also clears triglyceride-rich remnant particles; reduced HL activity allows these to persist longer in circulation, elevating fasting triglycerides. The resulting phenotype — elevated HDL-C alongside elevated triglycerides — is a recognized pattern at the LIPC locus.

The Evidence

The primary evidence for rs8034802 specifically comes from the Look AHEAD study¹¹ Look AHEAD study
Huggins et al. Do genetic modifiers of HDL-C and TG levels also modify their response to a lifestyle intervention in obesity and T2DM? Circ Cardiovasc Genet, 2013, which evaluated 82 SNPs across 31 lipid loci in 3,561 participants with obesity and type 2 diabetes who were randomized to intensive lifestyle intervention (ILI) versus usual diabetes care. Among the GWAS-identified lipid variants studied, rs8034802 was one of only two (alongside CETP rs3764261) associated with both higher baseline HDL-C and a nominally significant HDL-C increase specifically in the ILI group (P=0.013; treatment interaction P=0.046). The variant also showed associations with triglyceride changes during intervention (P<0.05). This makes rs8034802 notable not just as a baseline HDL-C modifier, but as a gene-environment interaction variant where the lifestyle context amplifies the effect.

The broader LIPC literature — including a meta-analysis of 87 studies (101,988 participants)²² meta-analysis of 87 studies (101,988 participants)
Liao et al. The cross-sectional study of hepatic lipase SNPs and plasma lipid levels. Medicine, 2020 — consistently shows that LIPC variants reducing HL activity raise HDL-C while simultaneously elevating triglycerides, LDL, and total cholesterol. A Brazilian cohort study³³ Brazilian cohort study
de Lima et al. LIPC -250A/G variant enhances carotid atherosclerosis. Atherosclerosis, 2020 found that LIPC variants with reduced HL activity paradoxically increased carotid atherosclerosis risk despite higher HDL-C — because the elevated HDL-C comes from accumulation of triglyceride-rich, cholesteryl ester-depleted HDL2 particles with impaired reverse cholesterol transport function.

Evidence for this specific rs8034802 variant is emerging — the Look AHEAD finding is a single large study. The broader LIPC locus has strong evidence, but rs8034802 specifically has not been replicated independently.

Practical Actions

For TT homozygotes (most common in Europeans, ~44% globally), hepatic lipase activity is at the reference level for this variant. Your HDL-C and triglycerides are not influenced by this locus.

For AT heterozygotes (~45% globally), the A allele confers moderately elevated baseline HDL-C. If you have obesity or type 2 diabetes, the Look AHEAD data suggest you may see above-average HDL-C gains from an intensive lifestyle intervention — making it particularly worthwhile to pursue. At the same time, the LIPC pattern of simultaneous HDL-C and triglyceride elevation means fasting triglycerides deserve as much attention as the HDL-C number on your lipid panel.

For AA homozygotes (~11% globally, up to 40% in East Asian populations), the dual elevation of HDL-C and triglycerides is most pronounced. The HDL-C reading may look encouraging on a standard panel, but asking your physician for apolipoprotein A-I (apoA-I) and fasting triglycerides gives a more complete picture of whether your HDL is genuinely protective. The HDL advantage is most preserved when saturated fat intake is limited and omega-3 polyunsaturated fats are emphasized.

Interactions

rs8034802 is located in the same LIPC gene as rs1532085 — the GWAS lead SNP for the LIPC locus (P=9.7×10⁻³⁶ in >100,000 Europeans). If your genetic test reports both variants, rs1532085 has much stronger population-level evidence for hepatic lipase regulation. rs8034802 adds the gene-lifestyle interaction dimension that rs1532085 studies have not specifically characterized.

CETP variants (rs3764261 and rs708272) were co-identified in the Look AHEAD study as the other major lifestyle-modifiable lipid locus. Combined high-HDL genotypes at both CETP and LIPC may amplify the HDL-C response to lifestyle intervention, though the cardiovascular benefit depends on whether the elevated HDL is functionally active (CETP mechanism) or large-particle accumulation (LIPC mechanism).

Adiponectin is one of the body's most protective metabolic hormones — secreted exclusively by fat cells, it simultaneously suppresses hepatic glucose output, activates AMPK in skeletal muscle, and shields artery walls from inflammation. People with high circulating adiponectin have meaningfully lower rates of type 2 diabetes, coronary artery disease, and ischemic stroke. rs822391 is an intronic C-to-T substitution in the first intron of ADIPOQ¹¹ ADIPOQ
The gene encoding adiponectin (also called APM1 or Acrp30), located at chromosome 3q27 — a locus strongly and repeatedly confirmed as the primary genetic determinant of circulating adiponectin levels in population studies, sitting 407 nucleotides into intron 1 at GRCh38 position chr3:186,846,014. The C allele (the minor allele, at roughly 20% frequency in Europeans and only 4% in Africans) has been associated with ischemic stroke risk and is implicated in modulation of adiponectin output at the 3q27 locus.

The Mechanism

Intronic variants in ADIPOQ influence adiponectin levels through several possible mechanisms: disruption of intronic enhancer elements²² intronic enhancer elements
Regulatory sequences within introns that recruit transcription factors to boost gene expression from a distance; intron 1 of ADIPOQ contains multiple such elements active in adipocytes, alterations in pre-mRNA splicing³³ pre-mRNA splicing
The process removing introns from precursor RNA; variants within the first few hundred nucleotides of an intron can affect splice site recognition and exon inclusion rates even without changing the consensus AG/GT dinucleotides, or tagging of nearby functional variants through linkage disequilibrium⁴⁴ linkage disequilibrium
The tendency for nearby genetic variants to be inherited together as a haplotype; rs822391 sits in the same ADIPOQ locus LD block as known functional variants including rs2241766 (T45G) and rs1501299 (+276G>T). The rs822391 C allele is the minor allele globally, with strong population stratification: frequency of roughly 20% in Europeans and South Asians, 10% in East Asians, and as low as 4% in African populations — a pattern consistent with population-specific selection acting on the ADIPOQ locus. The GTEx database identifies this variant as an eQTL for ADIPOQ-AS1 in testis tissue (NES −0.23, p=1.6×10⁻⁹), and the T allele shows positive regulatory effects in arterial tissue (NES +0.21, p=4.2×10⁻⁵), suggesting allele-specific effects on ADIPOQ-neighborhood gene regulation.

The Evidence

The most direct clinical evidence for rs822391 comes from a Korean case-control study by Cheong et al. (2011)⁵⁵ Cheong et al. (2011)
Six ADIPOQ polymorphisms were genotyped in a stroke vs. control cohort; rs822391 was among those showing significant association in both dominant and additive logistic regression models after adjustment for age and sex, which reported that the C allele (described in that paper as the T>C substitution, confirming C as the risk direction on the plus strand) was significantly associated with ischemic stroke risk (p<0.05). This is biologically coherent: adiponectin is an established anti-atherosclerotic and anti-thrombotic hormone, and variants that reduce its circulating levels — including rs822391 C allele carriers — face downstream consequences in cerebrovascular protection.

At the broader locus level, Heid et al. (2010)⁶⁶ Heid et al. (2010)
Genome-wide association analyses of 4,659 Europeans followed by replication in 13,795 additional subjects, n=18,454 total, identifying ADIPOQ as the dominant genetic determinant of plasma adiponectin established that the ADIPOQ 3q27 region explains approximately 6.7% of variance in circulating adiponectin levels in Europeans — the single largest genetic contributor to this phenotype. rs822391 lies within this locus, and the Jackson Heart Study (n>5,000 African Americans) included it among a panel of ADIPOQ variants examined for adiponectin associations with gender-specific effects, finding locus-wide signals concentrated in several correlated variants including rs16861205, a close neighbor at chr3:186,843,845.

On the intervention side, Sepidarkish et al. (2022)⁷⁷ Sepidarkish et al. (2022)
Systematic review and meta-analysis of 43 randomized controlled trials, n=3,434 participants across diverse populations demonstrated that omega-3 fatty acid supplementation raises circulating adiponectin with a pooled effect size of SMD 0.21 (95% CI 0.04–0.37, p=0.01), with the strongest effects at doses exceeding 2,000 mg EPA/DHA per day for more than 10 weeks. This intervention-level evidence directly informs the management of C allele carriers whose baseline adiponectin is already genetically suppressed.

Practical Actions

Carriers of the C allele cannot override the intronic regulatory change, but circulating adiponectin is modifiable through targeted nutrition. Long-chain omega-3 fatty acids (EPA and DHA) are the best-supported dietary upregulators of adiponectin, acting through PPAR-alpha activation in adipocytes to increase ADIPOQ transcription — a mechanism that partially compensates for genetically lower baseline secretion. Saturated fatty acids specifically suppress ADIPOQ promoter activity through competitive PPAR-gamma antagonism, so replacing saturated fat with mono- and polyunsaturated sources measurably raises adiponectin independent of total caloric intake.

Given the documented association with stroke risk, C allele carriers — particularly CT and CC individuals — benefit from monitoring the biomarkers that reflect the downstream consequences of lower adiponectin: fasting serum adiponectin, fasting insulin, and blood pressure. Early detection of hypoadiponectinemia (below 5 µg/mL) or elevated fasting insulin (above 8 µIU/mL) allows targeted intervention before vascular consequences develop.

Interactions

rs822391 lies within the same ADIPOQ intron 1 locus block as rs16861194 (−11426A>G upstream promoter), rs16861205 (intron 1 A>G), and nearby rs1501299 (+276G>T, intron 2). Individuals carrying risk alleles at multiple ADIPOQ locus variants — which tend to cluster in the same low-adiponectin haplotype — show substantially greater reductions in circulating adiponectin than any single variant predicts. The compounding of rs822391 C allele with rs2241767 G or rs1501299 T creates a high-priority metabolic target where direct adiponectin measurement is especially warranted. See related SNPs for individual variant profiles.